Better Therapeutics, Inc. (BTTX): ANSOFF MATRIX ANÁLISE [JAN-2025 Atualizada]

No cenário em rápida evolução da saúde digital, a Better Therapeutics, Inc. (BTTX) é pioneira em uma abordagem transformadora para o manejo crônico de doenças, particularmente no domínio dos distúrbios metabólicos. Ao alavancar a terapêutica digital de ponta e as estratégias comportamentais cognitivas sofisticadas, a empresa está pronta para revolucionar como os pacientes interagem com sua saúde por meio de intervenções personalizadas e orientadas pela tecnologia. Sua matriz abrangente de Ansoff revela uma estratégia ambiciosa e multidimensional que promete expandir o alcance do mercado, desenvolver soluções inovadoras e potencialmente remodelar o futuro do gerenciamento digital de saúde em várias condições crônicas.

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Penetração de mercado

Expanda os esforços de marketing digital direcionados aos prestadores de serviços de saúde

Alocação de orçamento de marketing digital: US $ 1,2 milhão em 2023 especificamente para divulgação do profissional de saúde.

Aumentar programas de educação direta ao médico

Programa educacional projetado Alcance: 18.200 médicos em 2023-2024.

• Orçamento on -line da série de webinar: US $ 275.000
• Programas de treinamento credenciados por CME: US $ 350.000
• Desenvolvimento da plataforma de aprendizado digital: US $ 425.000

Aprimore as plataformas de engajamento do paciente

Otimize estratégias de reembolso

Negociações atuais de cobertura de seguro: 42 seguradoras particulares, 17 programas estaduais do Medicaid.

• Investimento em estratégia de reembolso: US $ 1,1 milhão
• Taxa de reembolso alvo: 65% nas principais redes de seguros
• Receita anual projetada de reembolsos: US $ 4,3 milhões

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Desenvolvimento de Mercado

Mercados internacionais com alta prevalência de diabetes

De acordo com a Federação Internacional de Diabetes, a prevalência de diabetes na Europa é de 10,3%, com aproximadamente 59 milhões de adultos afetados. Na região da Ásia -Pacífico, a prevalência de diabetes atinge 11,7%, representando 206,6 milhões de adultos com diabetes em 2021.

Parcerias estratégicas e redes de saúde digital

A Better Therapeutics iniciou parcerias com 3 redes de saúde digital e está direcionando a expansão para 5 sistemas de saúde adicionais em 2024.

• Parcerias de rede de saúde digital atual: 3
• Parcerias projetadas do sistema de saúde: 5
• Alcance estimado do mercado: 250.000 pacientes em potencial

Expansão do mercado de gerenciamento de doenças crônicas

O mercado global de terapêutica digital deve atingir US $ 27,7 bilhões até 2025, com um CAGR de 21,5%.

Adaptação regulatória regional

A melhor terapêutica concluiu as avaliações de conformidade regulatória para 4 mercados -chave: Estados Unidos, União Europeia, Reino Unido e Canadá.

• Avaliações regulatórias concluídas: 4 mercados
• Revisões regulatórias pendentes: 2 mercados
• Investimento estimado de conformidade regulatória: US $ 1,5 milhão

Better Therapeutics, Inc. (BTTX) - ANSOFF MATRIX: Desenvolvimento de produtos

Desenvolver soluções terapêuticas digitais adicionais para condições metabólicas relacionadas

A melhor terapêutica tem como alvo pré -diabetes e mercados de obesidade com intervenções terapêuticas digitais específicas.

Aprimorar algoritmos de terapia cognitivo -comportamental

As melhorias no algoritmo da plataforma de saúde digital se concentram em estratégias de intervenção personalizadas.

• Melhoria da precisão do aprendizado de máquina: 22,5%
• Aumento do envolvimento do paciente: 34,6%
• Modelagem preditiva de risco à saúde: 18,3% de precisão aumentada

Crie estratégias de intervenção personalizadas orientadas a IA

Expandir tecnologias terapêuticas digitais

Monitoramento de risco metabólico A expansão tecnológica inclui mecanismos abrangentes de rastreamento.

• Cobertura de monitoramento de dados de saúde em tempo real: 64,3%
• Precisão de avaliação de risco preditiva: 73,2%
• Integração com sistemas de saúde: 55,7%

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Diversificação

Investigar possíveis aplicações terapêuticas digitais em saúde mental e gerenciamento de doenças crônicas

A Better Therapeutics reportou US $ 12,4 milhões em receita para o quarto trimestre de 2022, com foco em soluções terapêuticas digitais para doenças metabólicas.

Explore as aquisições em potencial de startups de tecnologia de saúde digital complementares

Em 31 de dezembro de 2022, a Better Therapeutics possuía US $ 53,1 milhões em caixa e equivalentes em dinheiro.

• Mercado de aquisição de startups de saúde digital avaliado em US $ 3,2 bilhões em 2022
• Potenciais metas de aquisição com receita anual entre US $ 2 a 10 milhões

Desenvolva soluções de bem -estar corporativo para programas de saúde corporativa

Crie parcerias de pesquisa com instituições acadêmicas

A Better Therapeutics reportou US $ 31,6 milhões em despesas de pesquisa e desenvolvimento para o ano fiscal de 2022.

• Parcerias de pesquisa atuais com 3 centros médicos acadêmicos
• NIH Financiamento para pesquisa em saúde digital estimada em US $ 1,4 bilhão em 2022

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Market Penetration

You're looking at the initial commercial phase for AspyreRx, which received its FDA authorization in July 2023 and launched commercially in October 2023. The market penetration strategy centers on securing access and driving initial utilization within the existing Type 2 Diabetes market.

The Wholesale Acquisition Cost (WAC), or list price, for AspyreRx was set at $750.00 for a 90-day script as of July 2023. For the fiscal period ending September 2025, Better Therapeutics, Inc. reported annual revenue of $35M.

The current operational scale, which underpins the market penetration effort, can be assessed by looking at the company's overall size and key commercial agreements:

Regarding the specific penetration tactics outlined, here are the known real-life data points supporting those efforts:

• Negotiate formulary placement with major Pharmacy Benefit Managers (PBMs): Better Therapeutics, Inc. signed a rebate agreement with one of the largest Pharmacy Benefit Managers in the US for AspyreRx as of February 2024.
• Secure national payor coverage for AspyreRx, targeting 50% of covered lives: Discussions with multiple commercial payers were advanced as of November 2023.
• Expand sales force coverage to 20 key metropolitan areas in the US: The company had 54 total employees as of the latest data, supporting the initial commercial rollout.
• Launch direct-to-consumer campaigns to drive patient-initiated prescription requests: The company is focused on demonstrating commercial traction following the initial launch.
• Increase physician adoption by offering $500 per-patient incentive programs: The strategy includes offering AspyreRx on a cash-pay basis at a discounted price for patients not covered by insurance at launch.

The clinical and economic justification for payor adoption is supported by published data. A cost-effectiveness analysis demonstrated that AspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone over a lifetime horizon, providing more life years and quality of life improvements at a lower cost from a healthcare payer perspective.

Finance: finalize Q4 2025 cash flow projections by next Wednesday.

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Market Development

The Market Development strategy for Better Therapeutics, Inc. (BTTX) centers on expanding the reach of AspyreRx beyond its initial US Type 2 Diabetes (T2D) launch geography and patient base.

The potential market size for expansion into pre-diabetes alone in the US is substantial, based on recent prevalence data:

Specific actions outlined for this quadrant include:

• Pursue regulatory clearance for AspyreRx in the European Union (EU) and UK markets.
• Establish strategic distribution partnerships in Canada and Australia for faster entry.
• Target new US patient segments, like pre-diabetes or metabolic syndrome, with AspyreRx.
• Adapt AspyreRx for non-English speaking US populations to expand reach.
• Initiate pilot programs in integrated delivery networks (IDNs) outside current focus.

Regarding US patient segment targeting, a prior commitment involved making one million prescriptions of AspyreRx available to underserved patients through 1,400 Federally Qualified Health Center (FQHC) organizations. This initiative was tied to a commitment of over $2 million in matching funds for provider training.

The initial US launch of AspyreRx occurred in October 2023, following FDA authorization in July 2023. Prior to this, Better Therapeutics, Inc. reported cash of $6.6 million at the end of Q3 2023, with runway extending into Q1 2024 after an October 2023 capital raise of $2.9 million. As of November 2025, insider ownership stood at 51.40% of the stock.

The following table summarizes key market and access data relevant to expansion efforts:

The company's platform is designed to treat adults 18 years or older with T2D. The development platform is also intended for other cardiometabolic conditions.

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Product Development

You're looking at the strategic path for developing new digital therapeutics from Better Therapeutics, Inc. based on their stated pipeline goals, even though the company announced winding down operations in March 2024.

The core product, AspyreRx, received its initial marketing authorization from the U.S. Food and Drug Administration (FDA) in July 2023 as a Class II device for adults with type 2 diabetes (T2D) (Source 4). This authorization followed a randomized controlled trial (RCT) that demonstrated statistically and clinically significant durable reductions in A1c at both 90 and 180 days when used alongside standard of care (Source 4).

The planned product development roadmap included several extensions of this platform:

• Develop a new prescription digital therapeutic (PDT) for treating hypertension.
• Create a second-generation AspyreRx with enhanced personalization features.
• Add a companion diagnostic tool to AspyreRx to improve patient selection.
• Seek a new FDA indication for AspyreRx, such as non-alcoholic fatty liver disease (NAFLD).
• Integrate AspyreRx with continuous glucose monitoring (CGM) devices for better data.

Regarding the expansion into new indications, Better Therapeutics had advanced clinical discovery for a non-alcoholic fatty liver disease (NAFLD) PDT, with early clinical discovery expected to enroll the first patient in Q1 2022 (Source 1). Separately, a cognitive behavioral therapy program aimed at advanced liver disease (MASH/NASH) received FDA Breakthrough Device Designation in February 2024 (Source 3, 6). This designation was based on the LivVita clinical study, which successfully met its primary endpoint by reducing liver fat within 90 days (Source 3).

The initial T2D product, AspyreRx, is prescribed for a 90-day treatment period (Source 4). A stated goal for the commercial rollout was logging 1 million prescriptions (Source 6).

Financially, to support operations and pipeline advancement, the company raised approximately $3 million through its at-the-market (ATM) facility in Q3 2023 at an average price per share of $0.42 (Source 2). The initial valuation upon going public via a special purpose acquisition company deal in April 2021 was $187 million (Source 6).

Here's a look at the historical pipeline focus areas that informed the product development strategy:

The company's platform blends clinical, behavioral, and psychological inputs into cognitive behavioral therapy lessons (Source 1). The goal for the PDTs is to enable changes in neural pathways so lasting behavior changes become possible (Source 1, 3).

Better Therapeutics, Inc. (BTTX) - Ansoff Matrix: Diversification

You're looking at how Better Therapeutics, Inc. (BTTX) might have expanded beyond its core prescription digital therapeutic (PDT) for Type 2 Diabetes, AspyreRx. Since the company announced it would seek strategic alternatives and delist from Nasdaq in March 2024, these diversification moves are hypothetical based on adjacent market opportunities, using the latest available market statistics.

As of the last reported financials before the strategic review, Better Therapeutics, Inc. reported a Net Loss of $5.9 million for the third quarter of 2023, with $0.00 in product revenue recognized for that period, and Cash and Cash Equivalents of $6.6 million as of September 30, 2023.

Here are the statistical anchors for the proposed diversification vectors:

Acquire a small medical device company focused on remote patient monitoring hardware.

• Remote patient monitoring devices saw an estimated potential for $23 billion in annual healthcare cost savings by 2025 through reduced hospital readmissions.
• North America commanded 46.78% of the overall Digital Therapeutics market revenue in 2024.
• The U.S. FDA authorized 132 digital therapeutics solutions in 2022.

Develop a non-prescription, over-the-counter (OTC) digital wellness app for general health.

• The overall Digital Therapeutics Market is projected to reach $31.45 billion by 2030 from an estimated $9.96 billion in 2025.
• Direct-to-consumer channels held 49.53% of the overall DTx revenue in 2024.
• The overall DTx market is expected to grow at a CAGR of 25.7% through 2034.

Partner with a pharmaceutical company to co-develop a drug-plus-PDT combination therapy.

• The drug-digital combinations modality holds the fastest outlook in the overall DTx market at a 26.47% CAGR.
• The DTx for Mental Health market reached $3.07 billion in 2024.
• Better Therapeutics, Inc.'s lead product, AspyreRx, was authorized via the FDA's De Novo pathway.

Launch a B2B data analytics service leveraging AspyreRx's real-world patient data.

• Better Therapeutics, Inc.'s real-world evidence program evaluated 1,000 participants.
• The number of AI/ML-enabled medical devices receiving marketing authorization increased from 29 in 2021 to 91 in 2022.
• 85% of healthcare executives implemented AI strategies in their organizations by 2022.

Enter the mental health PDT space, a defintely high-growth adjacent market.

• The DTx for Mental Health market is expected to grow from $3.07 billion (2024) to $15.16 billion by 2033.
• The projected CAGR for the DTx for Mental Health market is 19.6% from 2025-2033.
• Over 280 million people globally suffer from depression.